A Subcutaneously Administered Investigational RNAi Therapeutic, Fitusiran (ALN-AT3), Targeting Antithrombin for Treatment of Hemophilia: Interim Results in Patients with Hemophilia A or B

Volume
22
Pagination
76 - 76
Journal
HAEMOPHILIA
ISSN
1351-8216
Metadata
Show full item record
Authors
Pasi, KJ; Georgiev, P; Mant, T; Creagh, MD; Lissitchkov, T; Bevan, D; Austin, S; Hay, CR; Brand, B; Kazmi, R
URI
http://qmro.qmul.ac.uk/xmlui/handle/123456789/15464
Collections